Purine ring-opened 7-methylguanine, prepared in vitro by alkaline treatment of 7-methylguanosine or of methylated calf thymus DNA, was extensively characterized by chromatographic and spectral techniques as N5-methyl-N5-formyl-2,5,6-triamino-4-hydroxypyrimidine. This modified base chromatographed as an early-eluting peak on an ion-exchange column but separated into two interconvertible components after reversed-phase or porous-resin h.p.l.c. The two components were analyzed by thermal desorption mass spectrometry and 500 MHz 1H-n.m.r. spectroscopy. Their mass spectra were identical (M+ at m/z 183) and their n.m.r. spectra each exhibited the same two sets of resonances whose relative intensities were solvent-dependent. Analysis by h.p.l.c. showed interconversion of the two components and kinetic studies demonstrated that this reaction was a reversible first-order process. At equilibrium, k1 = k2 = 0.334 h-1 and delta G = 22.9 kcal/mol. These data indicated that the ring-opened 7-methylguanine exists as cis/trans isomers with restricted rotation about the amide bond. Treatment of rats with an intraurethral initiating dose of the carcinogen N-methylnitrosourea resulted in a high level of bladder epithelial DNA modification with 7-methylguanine, O6-methylguanine, and methyl phosphotriesters as major adducts at 2 h after instillation. Purine ring-opened 7-methylguanine, chromatographically identical to the in vitro products, was initially a minor adduct. However, it was the only persistent modification in the bladder epithelial DNA and eventually accounted for 72% of the total carcinogen binding after 21 days. A tumor-promoting regimen, involving dietary sodium saccharin, did not alter the repair or persistence of any of the methylated adducts. These data demonstrate that purine ring-opened 7-methylguanine, previously reported to exist in liver DNA after N,N-dimethylnitrosamine or 1,2-dimethylhydrazine treatment, is present in a carcinogen-target tissue and is considerably more persistent than O6-methylguanine or other DNA methylation products. The possible role of this adduct as a promutagenic lesion initiating urinary bladder carcinogenesis is discussed.
Acrolein, a reactive metabolite of cyclophosphamide, may be responsible for bladder cancer induced by cyclophosphamide. DNA methylase was isolated from the liver and urothelium of rats by high salt extraction of purified nuclei. Acrolein at 10 microM inhibited liver and bladder DNA methylase activity by 30-50%. Kinetic studies with the liver enzyme showed a competitive type of inhibition with a Ki of 6.7 microM. Both dithiothreitol and glutathione afforded protection to the enzyme when added to the assay. At near equimolar concentrations of glutathione to acrolein, the methylase retained 80-90% activity. An increase in DNA had no effect on the inhibition by acrolein, whereas increased amounts of protein protected against acrolein inhibition, suggesting that acrolein reacted with the DNA methylase protein. On the other hand, DNA that had been reacted with acrolein was unable to serve as a substrate for DNA methylase. As the DNA adducts increased the methylation of the DNA decreased. Thus, acrolein has the ability to react with DNA and the DNA methylase protein, either of which results in inhibition of DNA methylation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.